Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

i give it a six out of ten.

solid performance. all indicators generally positive but a longer term project than i expect most would like...... i still dream of thr heady days of +15c sp!

positives
ongoing recruiting sales positions
opportunity for decent organic growth through existing customers
seemed to yave turned the corner with labcon.

negatives
looks like still longway from cashflow positive.... decent stock on hand but hard to tell what that equates to in manufacturing cost. alot more sales required to cover salaries etc.

main outstanding is whats meant by 'medium term' re new agreements. i like the refetence to large name pharmaceutical companies, that could put a fire under things.

gltah